A roadmap for biomarker qualification

A collaborative effort between pharmaceutical companies, regulatory agencies and academia to qualify biomarkers for kidney toxicity provides a model for investigating and identifying reliable safety markers for preclinical applications.

Saved in:
Bibliographic Details
Published inNature biotechnology Vol. 28; no. 5; pp. 444 - 445
Main Authors Warnock, David G, Peck, Carl C
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.05.2010
Nature Publishing Group
Subjects
631/154/1438
631/154/2426/2145
631/154/53
692/308/2778
Agriculture
Animals
Bioinformatics
Biomarkers
Biomarkers, Pharmacological
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Collaboration
Drug-Related Side Effects and Adverse Reactions
Humans
Kidney - drug effects
Kidney - injuries
Kidney diseases
Life Sciences
Medical research
news-and-views
Pharmaceutical industry
Pharmaceutical Preparations - standards
Toxicity
Toxicity Tests - standards
United States
United States Food and Drug Administration
United States
Online AccessGet full text

Cover

More Information
Summary:A collaborative effort between pharmaceutical companies, regulatory agencies and academia to qualify biomarkers for kidney toxicity provides a model for investigating and identifying reliable safety markers for preclinical applications.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt0510-444